e-learning
resources
Monograph
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic
Sophie O'Reilly, Matthew Angeliadis, Ross Murtagh, Virginie W. Gautier
Source:
Eur Respir Monogr 2021; 94: 39-68
Journal Issue:
COVID-19
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Sophie O'Reilly, Matthew Angeliadis, Ross Murtagh, Virginie W. Gautier. Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. Eur Respir Monogr 2021; 94: 39-68
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Pandemic influenza: using evidence on vaccines and antivirals for clinical decisions and policy making
Source: Eur Respir J 2006; 27: 661-663
Year: 2006
From the bedside: upcoming new clinical strategies: novel strategies to combat respiratory viral infections
Source: International Congress 2017 – Scientific year in review
Year: 2017
Quality and methodology of clinical practice guidelines on antiviral pharmacotherapy for COVID-19 during the early phase of the pandemic
Source: Virtual Congress 2021 – COVID - 19: lessons learned
Year: 2021
Influenza surveillance and vaccination: new developments
Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice
Year: 2017
Barriers to new drug development in respiratory disease
Source: Eur Respir J 2015; 45: 1197-1207
Year: 2015
Barriers to new drug development in respiratory disease
Source: Eur Respir J 2016; 47: 356-357
Year: 2016
Latest insights and challenges in tuberculosis vaccine development
Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management
Year: 2019
Ebola: progress with vaccines
Source: International Congress 2015 – Pandemics and emerging infections
Year: 2015
Development of RSV antiviral treatment: where are we?
Source: International Congress 2019 – Respiratory syncytial virus infections throughout life
Year: 2019
Characterisation of clinical phenotypes is mandatory for the development of new drugs
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014
Drug development: news from “hot” early stage clinical trials: personalised immunotherapy for lung cancer
Source: International Congress 2017 – Scientific year in review
Year: 2017
New treatments for RSV and other viruses, including update on vaccines
Source: ERS Courses: Paediatric respiratory infections
Year: 2019
Confronting the next pandemic: a top-down or bottom-up approach?
Source: Annual Congress 2006 - Influenza: from avian flu to pandemia?
Year: 2006
Strategies for the prevention and management of coronavirus disease 2019
Source: Eur Respir J, 55 (4) 2000597; 10.1183/13993003.00597-2020
Year: 2020
Future prospects for improved influenza vaccines
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007
Facts and perspectives in the development of new anti-TB drugs
Source: Annual Congress 2008 - New insights into tuberculosis control
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept